In addition, Masuhiro et al. reported that similarly to first-generation EGFR-TKIs, osimertinib monotherapy appears to be less effective in patients with EGFR T790M-positive NSCLC with PE [12], this is consistent with our results in EGFR T790M-positive patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.